We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (5586)11/11/2019 10:40:34 AM
From: richardred1 Recommendation

Recommended By

  Read Replies (1) | Respond to of 6782
Added to ENZ today >3. Will CVS & Walgreens be doing lab testing in the future?

Message #5586 from richardred at 10/10/2019 11:22:40 AM


IMO Harbert is seeing what I'm seeing in ENZ IP. Reminds me so much of my successful LPDX pick. RE-
Enzo Biochem Unit Secures New York State Approval for Hepatitis B Virus Clinical Test
BY MT Newswires
— 12:20 PM ET 09/24/2019

Enzo Biochem Wins US Patent for Advanced Nucleic Acid Hybridization Probe Technology
BY MT Newswires
— 2:15 PM ET 08/05/2019

To: richardred who wrote (3456)9/25/2014 11:53:11 PM
From: richardred2 Recommendations Respond to of 5585

Nice surprise to come home tonight to- Bulls Eye # 3 this year LPDX-LipoScience :+ )

LabCorp Acquiring Cholesterol Tester LipoScience By AMY REEVES, INVESTOR'S BUSINESS DAILY

Posted 11:49 AM ET

Medical-testing giant Laboratory Corp. of America (NYSE: LH) agreed to buy startup LipoScience (NASDAQ: LPDX) for $85.3 million in cash Thursday, sending the latter's shares up more than 62% in the stock market today.

LipoScience makes a lipid profile test using nuclear magnetic resonance technology to measure a patient's cholesterol levels and help manage heart disease. The stock went public at 9 in January 2013, but was hammered for over a year, bottoming out below 3 earlier this month. In an email to clients Thursday, ISI Group analyst Michael Cherny wrote that the company's problems are probably behind it.

"We believe that LPDX's test is superior when used for managing patients, and the issues that the company has faced in the past have largely been due to market access (and) negotiating reimbursement rates with third-party vendors," he wrote. "Given our positive view on the test, we believe that LH's commercial infrastructure should drive broader test adoption by removing some of the barriers to market access. Additionally, some payers have been pushing back against tests offered by out-of-network labs, which had impacted LPDX. Given that LH is an in-network provider for most large plans, we expect the above-mentioned payer-related pressures to abate."

View Enlarged Image

By midmorning Thursday, LipoScience's stock was trading a bit below LabCorp's offer price of $5.25 a share. LabCorp's stock was down about 1%, near 103.

Follow Amy Reeves on Twitter: @IBD_AReeves.

Read More At Investor's Business Daily:
Follow us: @IBDinvestors on Twitter | InvestorsBusinessDaily on Facebook